Antisense oligonucleotides directed to ribonucleotide reductase R2 and uses thereof in the treatment of cancer
US7968526B2 · kind B2 · utility
0Cited by
6References
19Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 21, 2010 |
| Grant date | Jun 28, 2011 |
| Priority date | — |
| Expiry date | Jan 21, 2030 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2310/315
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides antisense oligonucleotides directed to a mammalian ribonucleotide reductase R2 gene and combinations of the antisense oligonucleotides with one or more chemotherapeutic agents for use in the treatment of cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.